Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biovitrum
Promising oncology project acquired from Axelar
September 24th, 2004
Biovitrum announced that the company has acquired a promising oncology project from Axelar AB, an innovative company established by leading researchers at the Karolinska Institute, and Karolinska Innovations AB. The project is targeting the growth of tumor cells and may lead to future treatment opportunities for various types of cancer. The project includes development of molecules that inhibit the IGF-1 receptor, which is involved in the growth of tumor cells in several ways. Through the agreement, Biovitrum gets access to a new chemical entity against cancer, which has demonstrated promising results in preclinical studies. The project will be...
Source: Food & Drug Law Weekly (2004-09-24)
|
